Table 1 Characteristic of selected studies in the meta-analysis
From: Prognostic and clinical significance of claudin-4 in gastric cancer: a meta-analysis
Author | Year/country | Patient number | Gender (M/F) | Age | Antibody source | Dilution | Cut-off (%) | Follow-up (month) | Quality score |
|---|---|---|---|---|---|---|---|---|---|
Li et al. | 2014/China | 142 | 94/48 | 61.4 | Invitrogen | NA | 50 | NA | 7 |
Liu et al. | 2013/China | 72 | 42/30 | 48.6 | Beckman | NA | 25 | 12–48 | 8 |
Zhu et al. | 2013/China | 329 | 238/91 | 57 | Zymed | 1:100 | 50 | 1–136 | 9 |
Jung et al. | 2011/Korea | 72 | 43/29 | 60.46 | DAKO | 1:200 | 50 | 2.7–48.8 | 8 |
Wu et al. | 2011/China | 98 | 59/39 | 63.5 | Abcam | NA | 50 | 6–76 | 8 |
Hwang et al. | 2010/Taiwan | 189 | 110/79 | 62 | Zymed | 1:100 | 50 | 12–60 | 8 |
Ohtani et al. | 2009/Japan | 124 | 89/35 | 66.8 | Zymed | 1:100 | 50 | 1–64 | 8 |
Kuo et al. | 2006/Taiwan | 93 | 56/37 | 64 | Santa Cruz | NA | 50 | NA | 7 |
Resnick et al. | 2005/USA | 146 | 76/70 | 71.1 | Zymed | 1:100 | 50 | 12–180 | 8 |